CStone Pharmaceuticals (HKG:2616) enrolled its first patient in its global multicenter phase 1B clinical trial for its CS5001 anti-tumor drug, according to a Thursday filing with the Hong Kong Exchange.
The drug is indicated for anti-tumor activity in both solid tumors and lymphomas, showing "robust" anti-tumor activity in its Phase 1A trials, the filing said.
Shares were down nearly 2% in morning trade Thursday.
Price (HKD): $2.49, Change: $-0.070, Percent Change: -2.73%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments